Business News Agency reported on December 7 that Rao Zihe, academician of the Chinese Academy of Sciences and president of Nankai University, said in his speech in Kunming on the 3rd that China’s bio-pharmaceutical industry is expected to develop into a pillar industry of 600-800 billion yuan, with key directions including the development of new vaccines and reforms. The industrialization of biotech drugs such as traditional vaccines, antibody drugs and protein drugs, research and product development of major disease diagnosis and detection technologies, and bioremediation and regenerative medicine technologies such as gene therapy and cell therapy.
According to Rao Zihe and academicians, China's biopharmaceutical industry has broad prospects, but currently faces challenges such as a weak foundation, low investment, lack of top talent, and weak innovation capabilities. Most of the biotechnology innovations and patents originate from developed countries. For example, 59% of biotechnology patents come from the United States, 19% from Europe, and 17% from Japan. The key development directions of China's biomedical industry include the following five aspects:
The first is to develop new vaccines and transform traditional vaccines. China is the country with the largest amount of vaccines in the world, and the number of people used each year amounts to hundreds of millions. The promotion and application of vaccines has made a significant contribution to the significant increase in life expectancy per capita in China, but at present, China still heavily uses vaccines developed 50 years ago or even earlier. The development of new vaccines and transformation of traditional vaccines is an inevitable trend, which will help greatly improve the prevention and control of major infectious diseases, and can also cultivate a vaccine industry of 100 billion to 150 billion yuan.
The second is the industrialization of biotechnology drugs such as antibody drugs and protein drugs. Biotech drugs have become the fastest-growing drugs in the world for malignancies, cardiovascular and cerebrovascular diseases, neurodegenerative diseases, diabetes, and autoimmune diseases that seriously endanger people's health. At present, China's biotech drug market is about 40 billion yuan in size, and it is expected to be cultivated into a 300-500 billion yuan industry in the future.
The third is the research and product development of major disease diagnosis and detection technologies. The outbreak of SARS, bird flu, tuberculosis, AIDS, and pandemic H1N1 influenza requires the development of diagnostic technologies and related industries. The future is expected to be cultivated into a diagnosis and testing market of about 50 billion yuan.
The fourth is to strengthen biological therapy such as gene therapy and cell therapy. At present, there are 6 stem cell therapeutic products in China undergoing clinical trials at different stages, and the development of nucleic acid drugs keeps pace with the world. By 2015, the potential market for global stem cell medicine will be about 80 billion U.S. dollars, and the nucleic acid drug market will reach 200 billion U.S. dollars. China is expected to cultivate a personalized treatment system with a scale of 100 billion yuan in the future.
Fifth, research and application of regenerative medicine technology. The global demand for organizational engineering products is huge, and it is expected that the organizational engineering products can open up 80 billion US dollars in the market. By 2020, 95% of transplanted cells, tissues and organs will be produced by tissue engineering techniques. There are many organ shortages caused by trauma, disease, inheritance and aging in China, and it is estimated that a regenerative treatment and rehabilitation market with a scale of RMB 50 billion can be cultivated.
According to Rao Zihe and academicians, China's biopharmaceutical industry has broad prospects, but currently faces challenges such as a weak foundation, low investment, lack of top talent, and weak innovation capabilities. Most of the biotechnology innovations and patents originate from developed countries. For example, 59% of biotechnology patents come from the United States, 19% from Europe, and 17% from Japan. The key development directions of China's biomedical industry include the following five aspects:
The first is to develop new vaccines and transform traditional vaccines. China is the country with the largest amount of vaccines in the world, and the number of people used each year amounts to hundreds of millions. The promotion and application of vaccines has made a significant contribution to the significant increase in life expectancy per capita in China, but at present, China still heavily uses vaccines developed 50 years ago or even earlier. The development of new vaccines and transformation of traditional vaccines is an inevitable trend, which will help greatly improve the prevention and control of major infectious diseases, and can also cultivate a vaccine industry of 100 billion to 150 billion yuan.
The second is the industrialization of biotechnology drugs such as antibody drugs and protein drugs. Biotech drugs have become the fastest-growing drugs in the world for malignancies, cardiovascular and cerebrovascular diseases, neurodegenerative diseases, diabetes, and autoimmune diseases that seriously endanger people's health. At present, China's biotech drug market is about 40 billion yuan in size, and it is expected to be cultivated into a 300-500 billion yuan industry in the future.
The third is the research and product development of major disease diagnosis and detection technologies. The outbreak of SARS, bird flu, tuberculosis, AIDS, and pandemic H1N1 influenza requires the development of diagnostic technologies and related industries. The future is expected to be cultivated into a diagnosis and testing market of about 50 billion yuan.
The fourth is to strengthen biological therapy such as gene therapy and cell therapy. At present, there are 6 stem cell therapeutic products in China undergoing clinical trials at different stages, and the development of nucleic acid drugs keeps pace with the world. By 2015, the potential market for global stem cell medicine will be about 80 billion U.S. dollars, and the nucleic acid drug market will reach 200 billion U.S. dollars. China is expected to cultivate a personalized treatment system with a scale of 100 billion yuan in the future.
Fifth, research and application of regenerative medicine technology. The global demand for organizational engineering products is huge, and it is expected that the organizational engineering products can open up 80 billion US dollars in the market. By 2020, 95% of transplanted cells, tissues and organs will be produced by tissue engineering techniques. There are many organ shortages caused by trauma, disease, inheritance and aging in China, and it is estimated that a regenerative treatment and rehabilitation market with a scale of RMB 50 billion can be cultivated.
Nonwoven Finished Products,Surgical Drape,Patient Surgical Gown,Sticker Protective Coverall,Delivery Pack,C-Section Pack,Surgical U Drape
XINLE HUABAO MEDICAL PRODUCTS CO.,LTD. , https://www.golbaltravel.com